Novacyt Raises €784,736: Capital Increase Oversubscribed by 125%
Novacyt announced on March 20, 2026, the closure of its capital increase with preferential subscription rights, having raised €784,736 through the issuance of 1,961,840 new ordinary shares.
The company raised €784,736 by issuing 1,961,840 New Shares at a unit price of €0.40. The total demand amounted to 2,456,286 New Shares, representing approximately 125.2% of the number of shares to be issued. The subscriptions on an irreducible basis reached 328,109 shares (€131,243.60), those on a reducible basis 592,383 shares (€236,953.20), and those on a free basis 1,535,794 shares (€614,317.60). The former owner of Southern Cross Diagnostics subscribed to 1,041,348 New Shares for an amount of €416,539.20. The service rate for free subscriptions was about 67.8% due to the oversubscription.
Allocation and Shareholder Impact
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The Board of Directors allocated the 1,041,348 shares not absorbed by the irreducible and reducible subscriptions to Ardenna PTY Ltd, the former owner of Southern Cross Diagnostics, who now holds 1.43% of the capital. A retention agreement for a minimum duration of 12 months was signed with Ardenna PTY Ltd, followed by a 6-month abstention period governing the terms of sale. Following the settlement-delivery scheduled for March 24, 2026, the share capital will amount to €4,839,205.87 divided into 72,588,088 ordinary shares. The equity per share will change from €0.67 before the increase to €0.66 after (before deduction of expenses). A shareholder holding 1% before the increase would see their stake diluted to 0.97%.
Related
SectorÉquipements et Services Médicaux›Équipements Médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 2025
Guidance from the release
La période de restructuration et d'intégration étant désormais clôturée, et l'activité stabilisée et moins risquée, nous nous sommes engagés à générer une croissance du chiffre d'affaires.
Croissance du chiffre d'affaires conforme aux attentes du marché; croissance semestrielle confirmée; pipeline solide pour 2026 et au-delà; groupe sans dette.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
